Skip to main content

Market Overview

Earnings Preview for Matinas BioPharma Hldgs


On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report. Benzinga's outlook for Matinas BioPharma Hldgs is included in the following report.

Earnings and Revenue

Based on management's projections, Matinas BioPharma Hldgs analysts modeled for EPS of $-0.03 per share on sales of $20.00 thousand. In the same quarter last year, Matinas BioPharma Hldgs also reported EPS at $-0.03 on sales of $89.81 thousand. If the company were to match the consensus estimate when it reports Monday, earnings would not change. Here's how the company's reported EPS has compared to analyst estimates in the past:

Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019
EPS Estimate -0.03 -0.03 -0.03 -0.03
EPS Actual -0.03 -0.04 -0.03 -0.03
Revenue Estimate 30.00 K 20.00 K 10.00 K 20.00 K
Revenue Actual 0 0 0 89.81 K

Stock Performance

Over the last 52-week period, shares of Matinas BioPharma Hldgs are up 32.91%.

Looking at these results, shareholders should be feeling unsatisfied with these results.

Don't be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 16:30:00 ET and can be accessed here:


Related Articles (MTNB)

View Comments and Join the Discussion!

Posted-In: Earnings